Last reviewed · How we verify
Folotyn
Folotyn is a Small molecule drug developed by Acrotech Biopharma Inc.. It is currently in discontinued development for Peripheral T-cell lymphoma. Also known as: Folotyn - (Pralatrexate), Pralatrexate.
At a glance
| Generic name | Folotyn |
|---|---|
| Also known as | Folotyn - (Pralatrexate), Pralatrexate |
| Sponsor | Acrotech Biopharma Inc. |
| Target | Folate transporter 1, Proton-coupled folate transporter, Dihydrofolate reductase |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | discontinued |
Approved indications
- Peripheral T-cell lymphoma
Common side effects
Key clinical trials
- Phase I/II Study of Carboplatin and Pralatrexate in Patients With Recurrent Platinum-Sensitive Ovarian, Fallopian or Primary Peritoneal Cancer (Phase 1)
- Phase 2 Study of Pralatrexate in Female Patients With Previously-treated Advanced or Metastatic Breast Cancer (Phase 2)
- Pilot Study Using Induction Chemo-immunotherapy Followed by Consolidation With Reduced Toxicity Conditioning and Allogenic Stem Cell Transplant in Advanced Stage Mature Non-anaplastic T-Cell or NK Lym (EARLY/Phase 1)
- Pralatrexate Combined With Chidamide Bridging Allogeneic Hematopoietic Stem Cell Transplantation for Refractory/Relapsed Peripheral T-cell Lymphoma (NA)
- Phase I and Clinical Pharamcologic Study of 10-Propargyl-10-Deazaaminopterin (PDX) in Combination With Probenecid in Adults With Advanced Solid Tumors (Phase 1)
- Pralatrexate and Bendamustine With 3 Gy TBI as a New Reduced Intensity Conditioning (RIC) Regimen for Allogeneic HCT for T-Cell Lymphoma Patients Who Are in Untreated R/R, or in Remission With MRD (Phase 1)
- A Phase II Study of 10-Propargyl-10-Deazaaminopterin (PDX) in Patients With Advanced Non-Small Cell Lung Cancer (Phase 2)
- Phase I/II Clinical Study of Pralatrexate in Japanese Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (Phase 1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Folotyn CI brief — competitive landscape report
- Folotyn updates RSS · CI watch RSS
- Acrotech Biopharma Inc. portfolio CI
Frequently asked questions about Folotyn
What is Folotyn?
Folotyn is a Small molecule drug developed by Acrotech Biopharma Inc., indicated for Peripheral T-cell lymphoma.
What is Folotyn used for?
Folotyn is indicated for Peripheral T-cell lymphoma.
Who makes Folotyn?
Folotyn is developed by Acrotech Biopharma Inc. (see full Acrotech Biopharma Inc. pipeline at /company/acrotech-biopharma-inc).
Is Folotyn also known as anything else?
Folotyn is also known as Folotyn - (Pralatrexate), Pralatrexate.
What development phase is Folotyn in?
Folotyn is in discontinued.
What does Folotyn target?
Folotyn targets Folate transporter 1, Proton-coupled folate transporter, Dihydrofolate reductase.
Related
- Target: All drugs targeting Folate transporter 1, Proton-coupled folate transporter, Dihydrofolate reductase
- Manufacturer: Acrotech Biopharma Inc. — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Peripheral T-cell lymphoma
- Also known as: Folotyn - (Pralatrexate), Pralatrexate